These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 24054565)
21. Anticancer activity of selected phenolic compounds: QSAR studies using ridge regression and neural networks. Nandi S; Vracko M; Bagchi MC Chem Biol Drug Des; 2007 Nov; 70(5):424-36. PubMed ID: 17949360 [TBL] [Abstract][Full Text] [Related]
22. Synergistic interaction of β-galactosyl-pyrrolidinyl diazeniumdiolate with cisplatin against three tumor cells. Deng L; Zhang E; Chen C Arch Pharm Res; 2013 May; 36(5):619-25. PubMed ID: 23494564 [TBL] [Abstract][Full Text] [Related]
23. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422 [TBL] [Abstract][Full Text] [Related]
24. Synergistic induction of cancer cell death and reduction of clonogenic resistance by cisplatin and FK228. Choudhary S; Sood S; Wang HC Biochem Biophys Res Commun; 2013 Jun; 436(2):325-30. PubMed ID: 23743194 [TBL] [Abstract][Full Text] [Related]
25. Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. Kendrick JE; Straughn JM; Oliver PG; Wang W; Nan L; Grizzle WE; Stockard CR; Alvarez RD; Buchsbaum DJ Gynecol Oncol; 2008 Mar; 108(3):591-7. PubMed ID: 18177927 [TBL] [Abstract][Full Text] [Related]
26. Synergistic cytotoxicity of recombinant human TNF and various anti-cancer drugs. Watanabe N; Niitsu Y; Yamauchi N; Ohtsuka Y; Sone H; Neda H; Maeda M; Urushizaki I Immunopharmacol Immunotoxicol; 1988; 10(1):117-27. PubMed ID: 2452179 [TBL] [Abstract][Full Text] [Related]
27. Enhancement of taxane-induced cytotoxicity and apoptosis by gossypol in human breast cancer cell line MCF-7. Karaca B; Atmaca H; Uzunoglu S; Karabulut B; Sanli UA; Uslu R J BUON; 2009; 14(3):479-85. PubMed ID: 19810142 [TBL] [Abstract][Full Text] [Related]
28. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin. Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583 [TBL] [Abstract][Full Text] [Related]
29. Comparison of artificial neural network and multiple linear regression in the optimization of formulation parameters of leuprolide acetate loaded liposomes. Arulsudar N; Subramanian N; Muthy RS J Pharm Pharm Sci; 2005 Aug; 8(2):243-58. PubMed ID: 16124936 [TBL] [Abstract][Full Text] [Related]
30. Synergistic effects between a copper-based metal Casiopeína III-ia and cisplatin. Davila-Manzanilla SG; Figueroa-de-Paz Y; Mejia C; Ruiz-Azuara L Eur J Med Chem; 2017 Mar; 129():266-274. PubMed ID: 28231523 [TBL] [Abstract][Full Text] [Related]
31. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice. Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185 [TBL] [Abstract][Full Text] [Related]
32. The application of artificial neural networks for phenotypic drug resistance prediction: evaluation and comparison with other interpretation systems. Pasomsub E; Sukasem C; Sungkanuparph S; Kijsirikul B; Chantratita W Jpn J Infect Dis; 2010 Mar; 63(2):87-94. PubMed ID: 20332568 [TBL] [Abstract][Full Text] [Related]
33. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. White S; Taetle R; Seligman PA; Rutherford M; Trowbridge IS Cancer Res; 1990 Oct; 50(19):6295-301. PubMed ID: 2400993 [TBL] [Abstract][Full Text] [Related]
34. Effect of bortezomib in combination with cisplatin and 5‑fluorouracil on 4T1 breast cancer cells. Yerlikaya A; Altıkat S; Irmak R; Cavga FZ; Kocacan SA; Boyaci I Mol Med Rep; 2013 Jul; 8(1):277-81. PubMed ID: 23660746 [TBL] [Abstract][Full Text] [Related]
35. Interaction of etoposide and cisplatin in an in vitro tumor model. Durand RE; Goldie JH Cancer Treat Rep; 1987; 71(7-8):673-9. PubMed ID: 3607781 [TBL] [Abstract][Full Text] [Related]
36. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs. Li LH; DeKoning TF; Wallace TL Cancer Res; 1987 Nov; 47(22):5894-900. PubMed ID: 3664490 [TBL] [Abstract][Full Text] [Related]
37. Potentiation of cisplatin cytotoxicity by lonidamine in primary cultures of human ovarian cancer. Orlandi L; Zaffaroni N; Gornati D; Veneroni S; Silvestrini R Anticancer Res; 1994; 14(3A):1161-4. PubMed ID: 8074467 [TBL] [Abstract][Full Text] [Related]
38. Experimental design and statistical analysis for three-drug combination studies. Fang HB; Chen X; Pei XY; Grant S; Tan M Stat Methods Med Res; 2017 Jun; 26(3):1261-1280. PubMed ID: 25744107 [TBL] [Abstract][Full Text] [Related]
39. Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents. Barret JM; Kruczynski A; Etiévant C; Hill BT Cancer Chemother Pharmacol; 2002 Jun; 49(6):479-86. PubMed ID: 12107553 [TBL] [Abstract][Full Text] [Related]
40. Anti-proliferative and pro-apoptotic effects from sequenced combinations of andrographolide and cisplatin on ovarian cancer cell lines. Yunos NM; Mutalip SS; Jauri MH; Yu JQ; Huq F Anticancer Res; 2013 Oct; 33(10):4365-71. PubMed ID: 24123004 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]